Published in Obesity and Diabetes Week, March 23rd, 2009
"INT131-007 is an important study designed specifically to extend the encouraging findings from our Phase 2a study and demonstrate the unique properties of INT131, a potent insulin sensitizer, in patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.